Yea Christopher — SEC Form 4 filings
SEC reporting owner CIK 1691102. 28 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2024-02-13 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 24 legs across 24 filings — 182,001 shares, $3,024,430 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 80.
- Largest priced transaction: sale of 33,800 shares @ $26.78 ($905,225) in KalVista Pharmaceuticals, Inc., filed 2026-05-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) | CHIEF DEVELOPMENT OFFICER | 28 | — | 24 legs · 182,001 sh · $3,024,430 | 80 |
Form 4 filings — Yea Christopher
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Disposition to issuer (D): 229,918 @ $0 · Disposition to issuer (D): 53,500 (derivative) · Disposition to issuer (D): 52,600 (derivative) · Disposition to issuer (D): 27,900 (derivative) · Disposition to issuer (D): 60,000 (derivative) · Disposition to issuer (D): 31,000 (derivative) · +5 more | EDGAR |
| 2026-05-29 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 33,800 @ $7.07 · Sale (S): 33,800 @ $26.78 · Option exercise (M): 33,800 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,966 @ $26.78 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,750 · Sale (S): 2,358 @ $26.78 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 1,774 · Sale (S): 1,108 @ $26.76 · Option exercise (M): 1,774 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,750 · Option exercise (M): 3,125 · Sale (S): 4,347 @ $15.57 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 1,774 · Sale (S): 1,109 @ $15 · Option exercise (M): 1,774 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,750 · Option exercise (M): 3,125 · Sale (S): 4,331 @ $13.45 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 87,390 @ $0.00 · Option exercise (M): 87,390 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 4,205 · Sale (S): 2,683 @ $14.48 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,431 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,954 @ $13.42 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2025-08-25 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,750 · Sale (S): 2,362 @ $13.22 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 4,203 · Sale (S): 2,649 @ $13.19 · Option exercise (M): 1,773 (derivative) @ $0 · Option exercise (M): 2,430 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 60,000 · Sale (S): 30,250 @ $15.69 | EDGAR |
| 2025-05-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,926 @ $11.31 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,750 · Sale (S): 2,317 @ $11.88 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 4,205 · Sale (S): 2,600 @ $11.84 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,431 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,918 @ $10.02 · Grant/award (A): 60,000 (derivative) @ $0 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 4,204 · Sale (S): 2,601 @ $9.82 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,430 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,963 @ $9.87 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2024-11-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 11,496 · Sale (S): 7,192 @ $9.26 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,431 (derivative) @ $0 · Option exercise (M): 7,291 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 3,125 · Sale (S): 1,916 @ $12.40 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 11,495 · Sale (S): 7,102 @ $12.01 · Option exercise (M): 1,773 (derivative) @ $0 · Option exercise (M): 2,430 (derivative) @ $0 · Option exercise (M): 7,292 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 18,789 · Sale (S): 11,610 @ $11.76 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,431 (derivative) @ $0 · Option exercise (M): 7,292 (derivative) @ $0 · Option exercise (M): 7,292 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 18,788 · Sale (S): 12,053 @ $14.11 · Option exercise (M): 1,774 (derivative) @ $0 · Option exercise (M): 2,430 (derivative) @ $0 · Option exercise (M): 7,292 (derivative) @ $0 · Option exercise (M): 7,292 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Sale (S): 39,886 @ $15.01 | EDGAR |
| 2024-02-13 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 60,000 · Grant/award (A): 29,167 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1691102 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →